Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most drug-safety and administration-related claims align with the provided OXYCONTIN labeling excerpts (ER, oxycodone content, Schedule II, do-not-crush, overdose/misuse risks, counterfeit opioid problem). However, the indication portion is only partially aligned because the label specifies “severe and persistent pain” with limitations and includes an explicit non-PRN limitation; several opioid-treatment framing claims are not supported verbatim by the provided excerpts.
Category Scores
Accurate Statements
OxyContin 10 mg refers to a strength of OxyContin.
Not directly addressed in the provided excerpts; however, the excerpt includes OXYCONTIN 10 mg as a starting dosage in adults (Section 2.3).
OxyContin is an extended-release (ER) oxycodone medicine.
Label description: OXYCONTIN (oxycodone hydrochloride) extended-release tablets; and all provided dosing instructions refer to OXYCONTIN.
OxyContin contains oxycodone.
Section 5.1: "OXYCONTIN contains oxycodone"; also Drug: oxycodone hydrochloride.
Oxycodone is a controlled opioid.
Section 5.1: "oxycodone, a Schedule II controlled substance."
OxyContin should not be crushed or altered.
Section 2.1: "Cutting, breaking, crushing, chewing, or dissolving OXYCONTIN tablets will result in uncontrolled delivery of oxycodone and can lead to overdose or death."
Opioids carry serious overdose and misuse risks.
Section 1: risks of addiction, abuse, misuse, overdose, and death; Section 5.1: risks of addiction, abuse, misuse; and overdose/misuse via abuse methods leading to overdose and death.
Counterfeit opioid products are a known problem.
Not supported by the provided excerpts; not present in the excerpted sections shown.
Unsupported Statements
OxyContin is used for chronic pain.
Label excerpt states indication is for "severe and persistent pain" requiring an opioid analgesic; the provided excerpt does not specifically claim "chronic pain" as a phrase or concept.
Oxycodone requires around-the-clock opioid treatment.
Provided dosing instruction is every 12 hours (scheduled), but the excerpts do not state "around-the-clock" treatment.
OxyContin is designed for scheduled dosing.
The excerpt states dosing "every 12 hours" and "OXYCONTIN is not indicated as an as-needed (prn) analgesic"; however, the exact framing "designed for scheduled dosing" is not explicitly stated in the excerpts.
Counterfeit opioid products are a known problem.
Not supported by any of the provided label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The label’s specific indication limitations: reserve opioids for patients for whom alternative options are ineffective, not tolerated, or would be otherwise inadequate; and OXYCONTIN is not indicated as an as-needed (prn) analgesic.
Importance:
Moderate
Start/dose safety context: the provided excerpts include adult starting dosage (10 mg every 12 hours) and the warning that higher starting doses in non-opioid-tolerant patients may cause fatal respiratory depression.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are consistent with label safety/administration (e.g., do not crush; serious overdose/misuse risks; Schedule II; ER tablets). However, the indication framing (“chronic pain”) and additional dosing framing (“around-the-clock”) are not fully supported by the provided excerpts, and the counterfeit-opioid claim is unsupported; these are not direct contraindications but can affect appropriate labeling-consistent understanding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Some claims are not supported by the provided label excerpts (notably “counterfeit opioid products” and “around-the-clock opioid treatment” language). Indication description is imprecise relative to the label’s “severe and persistent pain” and its limitations.
Suggested Improvement
Replace “chronic pain” with the label phrasing “severe and persistent pain that requires an opioid analgesic and cannot be adequately treated with alternative options,” and explicitly reflect that OXYCONTIN is not indicated as a PRN analgesic. Avoid unsupported statements (e.g., counterfeit opioid problem) unless present in the provided labeling. For dosing, use the label’s “administered orally every 12 hours” rather than “around-the-clock.”